Chemomab Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary

Chemomab Therapeutics

14/11/2024 14:16

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 1 cent​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -34 cents.  The lone analyst forecast
for the quarter was for a loss of one cent per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 1 cent​.
    * The company reported a quarterly loss of $3.48 million.
    * Chemomab Therapeutics Ltd shares had risen by 10.8% this
quarter and gained 241.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is 9.00 
This summary was machine generated from LSEG data November 14 at
02:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.01          -0.01          Met
 Jun. 30 2024      -0.01          -0.26          Missed